A comparison of the MeltPro® HPV Test with the Cobas® HPV Test for detecting and genotyping 14 high-risk human papillomavirus types
- 73 Downloads
The clinical performance of the newly developed MeltPro® HPV Test, based on multicolor melting curve analysis, was evaluated and compared with the commercially available Cobas® HPV Test for detection of HPV and genotyping of HPV-16 and HPV-18. A total of 1647 cervical samples were analyzed with both tests. The agreement values were 96.2% for HPV detection, 99.6% for HPV-16 identification, and 99.7% for HPV-18 identification. All genotyping results from MeltPro® HPV Test showed that HPV-52, HPV-58, and HPV-16 were the most common types in this study. Intra-laboratory reproducibility studies showed 97.8% agreement while inter-laboratory reproducibility studies showed 96.9% agreement for the MeltPro® HPV Test. The MeltPro® HPV Test and Cobas® HPV Test are highly correlative and are useful for monitoring HPV infection.
We thank National Natural Science Foundation (81401724 to Y. Liao), Key Project of Cooperation Program for University and Industry of Fujian Province (2013Y4008 to Y. Xu) and Cooperation Program for University and Industry of Xiamen City (3502Z20173013 to Y. Liao) for financial support.
Compliance with ethical standards
Conflict of interest
Q. Li holds equity interest in Zeesan Biotech. All of other authors declare that they have no conflict of interest. The MeltPro® HPV test reagents were kindly provided by Zeesan Biotech.
Humam/animal rights statement
This article does not contain any studies with human participants or animals performed by any of the authors.
- 2.Henry CK, Maribel A, Claire T, Paula W, Alexandra S, Boyka S, Clare G, Helene B, Christopher R, Robin D, Mina D, Jean M, Andrew B, Andrew T, Sue M, Julian P (2009) HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomized controlled trial. Lancet Oncol 10:672–682CrossRefGoogle Scholar
- 3.World Health Organization (2010) Human papillomavirus laboratory manua. Section 5:35–63Google Scholar
- 8.Kleter B, Van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, Ter Schegget J, Lindeman J, Harmsel BT, Burger M, Quint W (1999) Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 37:2508–2517PubMedPubMedCentralGoogle Scholar
- 11.Cuzick J, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, Liddle S, Dina R, McCarthy J, Buckley H, Bergeron C, Soutter WP, Lyons D, Szarewski A (2010) Performance of the Abbott real time high-risk HPV test in women with abnormal cervical cytology smears. J Med Virol 82:1186–1191CrossRefPubMedGoogle Scholar
- 12.Hwang Y, Lee M (2012) Comparison of the AdvanSure human papillomavirus screening real-time PCR, the Abbott real time high risk human papillomavirus test, and the hybrid capture human papillomavirus DNA test for the detection of human papillomavirus. Ann Lab Med 32:201–205CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Geraets DT, Cuschieri K, de Koning MN, van Doorn LJ, Snijders PJ, Meijer CJ, Quint WG, Arbyn M (2014) Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control. J Clin Microbiol 52:3996–4002CrossRefPubMedPubMedCentralGoogle Scholar